Angiotensin II (medication)

Angiotensin II
Clinical data
Trade names	Giapreza
Other names	Ang II
AHFS/Drugs.com	Monograph
License data	US DailyMed: Angiotensin II;
Routes of; administration	Intravenous injection
Drug class	Vasoconstrictor
ATC code	C01CX09 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	None
Metabolism	Proteolysis by glutamyl aminopeptidase, angiotensin converting enzyme 2
Metabolites	Angiotensin III, angiotensin-(1-7)
Elimination half-life	Less than one minute (IV administration)
Identifiers
	IUPAC name L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine;
CAS Number	4474-91-3;
PubChem CID	172198;
DrugBank	DB11842;
ChemSpider	150504;
UNII	M089EFU921;
KEGG	D02014; as salt: D11142;
CompTox Dashboard (EPA)	DTXSID30196288 ;
Chemical and physical data
Formula	C50H71N13O12
Molar mass	1046.197 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N;
	InChI InChI=InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1; Key:CZGUSIXMZVURDU-JZXHSEFVSA-N;

Angiotensin II, sold under the brand name Giapreza, is a medication that is used to treat hypotension resulting from septic shock or other distributive shock. It is a synthetic vasoconstrictor peptide that is identical to human hormone angiotensin II. The Food and Drug Administration approved the use of angiotensin II in December 2017 to treat low blood pressure resulting from septic shock.

The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is approved as a generic medication.